Prosecution Insights
Last updated: November 20, 2026
Application No. 19/069,419

MEDICAL MANIPULATOR AND MEDICAL MANIPULATOR SYSTEM

Non-Final OA §102§103§DOUBLEPATENT
Filed
Mar 04, 2025
Priority
Mar 08, 2024 — provisional 63/562,855 +8 more
Examiner
BERTRAM, ERIC D
Art Unit
3792
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Olympus Corporation
OA Round
1 (Non-Final)
81%
Grant Probability
Favorable
1-2
OA Rounds
1y 5m
Est. Remaining
93%
With Interview

Examiner Intelligence

Grants 81% — above average
81%
Career Allowance Rate
1058 granted / 1302 resolved
+11.3% vs TC avg
Moderate +12% lift
Without
With
+11.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
49 currently pending
Career history
1354
Total Applications
across all art units

Statute-Specific Performance

§101
4.1%
-35.9% vs TC avg
§103
35.8%
-4.2% vs TC avg
§102
29.8%
-10.2% vs TC avg
§112
12.4%
-27.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1302 resolved cases

Office Action

§102 §103 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Species A, Species I, Species 1 and Species W in the reply filed on 9/21/2026 is acknowledged. Claims 5, 6, 16 and 17 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected SPecies, there being no allowable generic or linking claim. Information Disclosure Statement The information disclosure statements (IDS) submitted on 3/4/2025, 6/2/2025, 6/12/2025, 8/13/2025 and 9/21/2026 were filed in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-4, 8-15 and 19-20 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Kawaura et al. (US 2012/0004503, hereinafter Kawaura). Regarding claims 1-4, 8, 10, 11, 13-15, 19 and 20, Kawaura discloses a medical manipulator, as seen in at least figures 2-6. The manipulator has a flexible body 42 and at least two arms 33,34 each having a first bending portion 37 and a second bending portion 38 proximal to the first bending portion, such that the first and second bending portions are each attached to an artificial muscle in the form of a wire that bendably drives each portion in two or four directions (par. 0044). Each arm has a channel 48,49 through which tools (i.e., treatment manipulators) are inserted from the proximal end of the manipulator through an insertion manipulator 16/29 and controlled at the proximal end using a drive device 28/31 (fig. 2, par. 0042, 0044, 0047, 0056-0059). Regarding claim 9, the arm can include end effector 53 at the distal end (fig. 5 and par. 0049). Regarding claim 12, each arm is inserted into and extends through a hole/cutout in the distal end opening of the insertion manipulator when bent (fig. 4). Claims 1-4, 7, and 10 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Ueda (US 5,897,488). Regarding claims 1-4, 7 and 10, Ueda discloses a medical manipulator with a flexible body 502 and an arm as seen in figure 23 with a first bending portion 503 and a second bending portion 504 proximal to the first bending portion, such that the first and second bending portions are each attached to an artificial muscle 506/507 in the form of an actuator and wire that bendably drives each portion in at least two directions (Col. 14, line 55-Col. 15, line 13). The first bending portion can have 3 artificial muscles 506/507 arranged in parallel along the axis of the arm, as seen in figure 24A and 24 B (Col. 15, lines 14-23). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 7 and 18 are rejected under 35 U.S.C. 103 as being unpatentable over Kawaura in view of Ueda (US 5,897,488). Kawaura discloses the applicant’s basic invention, including an artificial muscle in the form of a wire, but is silent as to there being multiple wires attached to the first bending portion. Ueda also discloses a medical manipulator and thus is analogous art with Kawaura. Ueda discloses a flexible body 502 and an arm as seen in figure 23 with a first bending portion 503 and a second bending portion 504 proximal to the first bending portion, such that the first and second bending portions are each attached to an artificial muscle 506/507 in the form of an actuator and wire that bendably drives each portion in at least two directions (Col. 14, line 55-Col. 15, line 13). The first bending portion can have 3 artificial muscles 506/507 arranged in parallel along the axis of the arm, as seen in figure 24A and 24 B (Col. 15, lines 14-23). Therefore, it would have been obvious to one of ordinary skill in the art before the applicant’s effective filing date to modify Kawaura to include multiple wires arranged in parallel along the axis of the arm, as taught by Ueda, in order to allow for maximum control the of the bending of the device. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-4, 7-11, 13-15, 18, 19 and 20 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 9-11 and 19-20 of copending Application No. 19/074,7766 (reference application). Although the claims at issue are not identical, claims 1-4, 8-11, 13-15, 19 and 20 are not patentably distinct from each other because the copending claims anticipate the current claims. Regarding claims 7 and 18, the artificial muscle is disclosed in the copending claims as extending along a longitudinal axis, but the copending claims are silent as to there being multiple artificial muscles. However, it has been held that the mere duplication of parts has no patentable significance unless a new and unexpected result is produced (In re Harza, 274 F.2d 669, 124 USPQ 378 (CCPA 1960)). In this case, adding more muscles will expectedly result in the manipulation of the bending portions. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. See attached PTO-892 especially US 5,531,664, which discloses a bendable medical manipulator. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Eric D Bertram whose telephone number is (571)272-3446. The examiner can normally be reached Monday-Friday 7am-4pm Central Time. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jennifer McDonald can be reached at 571-270-3061. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Eric D. Bertram/Primary Examiner, Art Unit 3796
Read full office action

Prosecution Timeline

Mar 04, 2025
Application Filed
Oct 28, 2026
Non-Final Rejection mailed — §102, §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12796927
Systems, Devices, Components and Methods for Detecting the Locations of Sources of Cardiac Rhythm Disorders in a Patient's Heart
3y 0m to grant Granted Nov 17, 2026
Patent 12788980
NANOSECOND PULSED ELECTRIC FIELD SYSTEM
2y 9m to grant Granted Nov 10, 2026
Patent 12788296
Wearable Multi-Modal Sensing Device for Real-Time Neurological Monitoring and Disorder Detection
1y 10m to grant Granted Nov 10, 2026
Patent 12779235
WEARABLE CARDIOVERTER DEFIBRILLATOR (WCD) SYSTEM REACTING TO HIGH-AMPLITUDE ECG NOISE
3y 6m to grant Granted Nov 03, 2026
Patent 12773565
IMPLANTABLE MEDICAL DEVICES FOR MULTI-CHAMBER PACING
3y 5m to grant Granted Oct 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
81%
Grant Probability
93%
With Interview (+11.9%)
3y 2m (~1y 5m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1302 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month